Seagen Inc (NASDAQ:SGEN)
| 161.22 Delayed Data As of 4:14pm ET |  -4.99 / -3.00%Today’s Change | 133.20 Today|||52-Week Range 213.94 | -7.95% Year-to-Date |
Latest SGEN News | Press Releases
| Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA Sep 22 / Zacks.com - Paid Partner Content | Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer Sep 21 / Zacks.com - Paid Partner Content |
| Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised) Sep 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 166.21 |
| Today’s open | 165.32 |
| Day’s range | 159.89 - 165.32 |
| Volume | 17,964 |
| Average volume (3 months) | 733,786 |
| Market cap | $28.4B |
Data as of 4:14pm ET, 09/24/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -168.94% |
| Earnings growth (next 5 years) | +23.00% |
| Revenue growth (last year) | +137.32% |
| P/E ratio | 48.4 |
| Price/Sales | 14.67 |
| Price/Book | 8.10 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | +0.91 | +0.83% |
| CTLTCatalent Inc | +0.38 | +0.27% |
| ALNYAlnylam Pharmaceutic... | +0.32 | +0.17% |
| ---- |
Data as of 4:15pm ET, 09/24/2021
Financials
| Next reporting date | October 28, 2021 |
| EPS forecast (this quarter) | -$0.57 |
| Annual revenue (last year) | $2.2B |
| Annual profit (last year) | $613.7M |
| Net profit margin | 28.21% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Bothell, Washington |
Forecasts
